 |
|
|
| |
Primary and Secondary Analyses of Emergent Drug Resistance through Week 96 from
the Phase 3 Studies of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF
|
| |
| |
Reported by Jules Levin
International Workshop on HIV & Hepatitis
Virus Drug Resistance and Curative Strategies
June 4-8, 2013
Toronto, Canada
KL White*, R Kulkarni, ME Abram, M Rhee, M Fordyce, and MD Miller
Gilead Sciences, Foster City, CA, USA
|
| |
|
|
|
|
|
